Study: No Heart Risk with Smoking-Cessation Meds

In a large, head-to-head comparison trial of major smoking-cessation therapies, use of the medications was not associated with an increased risk for heart attack or stroke, researchers reported.

The incidence of major cardiovascular events was low over a year of follow-up in users of varenicline (Chantix), bupropion hydrochloride (Zyban), nicotine-replacement therapy (NRT), and placebo, and adverse events did not differ by treatment.

There was also no evidence of an effect of any active drug versus placebo on time to cardiovascular event, blood pressure, or heart rate over 12 weeks of treatment, 30 days post-treatment, and up to 52 weeks of follow-up.

No Heart Risk with Smoking-Cessation Meds

Read the entire post at MedPageToday.com